Real-world experience and analyses of the performance of ixekizumab as first-line biologic agent versus second-line (or higher) biologic agent in the treatment of chronic plaque psoriasis.

Goon, Peter Kin Cho; Lim, Hai-Yee; Summerfield, Liz; Banfield, Cedric Charles; Sudhoff, Holger; Mallett, Dick

Goon, Peter Kin Cho; Lim, Hai-Yee; Summerfield, Liz; Banfield, Cedric Charles; Sudhoff, Holger; Mallett, Dick.

Afiliação

Goon PKC; Peterborough City Hospital, North West Anglia Foundation Trust (NWAFT), Peterborough, UK.
Lim HY; Peterborough City Hospital, North West Anglia Foundation Trust (NWAFT), Peterborough, UK.
Summerfield L; Peterborough City Hospital, North West Anglia Foundation Trust (NWAFT), Peterborough, UK.
Banfield CC; Peterborough City Hospital, North West Anglia Foundation Trust (NWAFT), Peterborough, UK.
Sudhoff H; University Hospital of Bielefeld, Bielefeld, Germany.
Mallett D; Peterborough City Hospital, North West Anglia Foundation Trust (NWAFT), Peterborough, UK.

Int J Dermatol ; 60(8): e319-e320, 2021 Aug.

Article em En | MEDLINE | ID: mdl-33817799

Assuntos

Fatores Biológicos; Psoríase; Anticorpos Monoclonais Humanizados; Humanos; Psoríase/tratamento farmacológico; Índice de Gravidade de Doença; Resultado do Tratamento

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Fatores Biológicos Limite: Humans Idioma: En Revista: Int J Dermatol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google